PubMed
Ipamorelin, a new growth hormone-releasing peptide
Johansen PB, Nowak J, Skjaerbaek C, et al. Eur J Endocrinol. 2001
GH SecretagoguesCompoundableA
Ipamorelin
NNC 26-0161
Ipamorelin is a selective pentapeptide growth hormone secretagogue and ghrelin receptor agonist notable for stimulating robust GH release with minimal effect on cortisol or prolactin — making it one of the most selective and well-tolerated GHRP compounds. Frequently combined with CJC-1295 for synergistic GH pulse amplification and sustained IGF-1 elevation. Compoundable with prescription.
Last reviewed . First published . By the PeptIQ team.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 7
- Research grade
- A
- Experience
- 99
- Activity
- 70
Overall check-ins
Trackers & reports
Overview
About Ipamorelin
Ipamorelin is a selective pentapeptide growth hormone secretagogue and ghrelin receptor agonist notable for stimulating robust GH release with minimal effect on cortisol or prolactin — making it one of the most selective and well-tolerated GHRP compounds. Frequently combined with CJC-1295 for synergistic GH pulse amplification and sustained IGF-1 elevation. Compoundable with prescription.
- Category
- GH Secretagogues
- Regulatory status
- Compoundable
- Also known as
- NNC 26-0161
- Self-reports
- 102
Community
What 102 users report
102 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
236
Sleep
236
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
2
Headache
2
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.05 to ≥ 5 mg (open-ended top bucket)
0.05–0.1 mg
12
0.1–0.2 mg
63
0.2–0.4 mg
137
0.4–0.6 mg
22
5+ mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 98% said they felt similar to their last entry, 2% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 44 repeat reporters
Research
Sources (5)
- Wiki study page →Source
- Wiki study page →Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
- Wiki study page →Source
ClinicalTrials.gov
Ipamorelin growth hormone studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. European journal of endocrinology. 1998
- Wiki study page →Source
PubMed
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism
Lu Z, Ngan MP, Liu JYH, et al. Physiology & behavior. 2024
Tools
Explore more
Explore
More ways to learn about Ipamorelin from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about Ipamorelin?
This page summarizes 102 anonymized self-reports from PeptIQ users who track Ipamorelin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Ipamorelin?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Ipamorelin?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Ipamorelin safe to use?
This wiki does not assess safety or recommend use. Ipamorelin is listed as Compoundable. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Ipamorelin?
This wiki summarizes observational community reports and linked citations for Ipamorelin. It does not assert therapeutic benefits. See the sources list on this page and the educational profile for Ipamorelin for study-level context — not medical advice.
What is the legal status of Ipamorelin?
Ipamorelin is listed in PeptIQ as Compoundable. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Ipamorelin?
Safety data quality for Ipamorelin varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Ipamorelin?
This page links 5 sources for Ipamorelin. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.